Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
17 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
PROPHARMA from Ottignies-Louvain-la-Neuve, company number BE0645717815, closed financial year 2025 with a result of € 84,153 after tax. For that financial year PROPHARMA recorded a gross margin of € 405,998 and equity of € 250,000. Compared with financial year 2024, the result moved from € 140,559 to € 84,153. The company is profitable. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on May 27, 2026.
€ 250,000
▼ 32% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 84,153
▼ 40% vs 2024
Profit after tax over the fiscal year.
€ 195,358
▼ 60% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 204,039 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
3.1
Average over the fiscal year, from the social balance sheet.
€ 246,597
▲ 28% vs 2024
€ 79,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 40,538
▲ € 36,844 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 143,424
▼ 10% vs 2024
€ 16,205 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.
€ 282,045
▲ 26% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 27,047
▼ 38% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 314,503 | € 409,365 | € 424,169 | € 405,998 | ▼ 4% |
| Profit after taxes | € 79,975 | € 144,124 | € 140,559 | € 84,153 | ▼ 40% |
| Equity | € 479,326 | € 529,326 | € 369,885 | € 250,000 | ▼ 32% |
| Total debts | € 380,448 | € 497,728 | € 732,851 | € 665,541 | ▼ 9% |
| Cash | € 272,667 | € 440,647 | € 487,211 | € 195,358 | ▼ 60% |
| Land & buildings | € 208,629 | € 193,976 | € 179,336 | € 167,936 | ▼ 6% |
| Retained profit | € 279,326 | € 329,326 | € 169,885 | € 50,000 | ▼ 71% |
| Dividend | € 0 | € 94,124 | € 300,000 | € 204,039 | ▼ 32% |
| Bank debt | € 190,494 | € 175,058 | € 159,369 | € 143,424 | ▼ 10% |
| Balance sheet total | € 859,774 | € 1,027,054 | € 1,102,736 | € 915,541 | ▼ 17% |
| Employees (FTE) | 1.8 | 2.5 | 3.1 | 3.1 |
Key figures of PROPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PROPHARMA?
What happened at PROPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 84,153 (▼ 40% vs 2024). Source: NBB ↗
- New establishment in Ottignies-Louvain-la-Neuve. KBO
- Start of the company according to the CBE. KBO
In short
From € 79,975 profit in 2022 to € 84,153 profit in 2025.
Paid € 135,748 in corporate taxes since 2022.
Best year ever: 2023, with € 144,124 profit.
On average € 131,000 of value added per employee in 2025.
A new publication or filing at PROPHARMA? We notify you, reason included.
Follow PROPHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Vincent CLABOTS
Director
Establishments
Establishment units
Physical locations of this company
Place de l'Accueil 10 box XXX
1348 Ottignies-Louvain-la-Neuve
Place de l'Accueil 10 box 29
1348 Ottignies-Louvain-la-Neuve
Active since 7 March 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 17 companies are registered at this address.
All companies at this address →ESPACE VISION
€ 449,587 gross margin · 2025
DIMAGES
€ -2,531 gross margin · 2025
PHARMACIE DE LAUZELLE
€ 881 gross margin · 2025
SKIMAGES
€ 15,042 gross margin · 2025
FONCIERE DE LOUVAIN-LA-NEUVE
€ 19.4 million revenue · 2025
+12 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0645.717.815
- VAT number
- BE 0645.717.815
- Registered office
- Place de l'Accueil 10 bus XXX, 1348 Ottignies-Louvain-la-Neuve
- Names & denominations
- PROPHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 January 2016
- Peppol
- Active · Active since 16 Dec 2025
- Contact
- propharma-lln.be [email protected]
- Activities · NACE
Detailhandel in farmaceutische producten